美国新诊断无脾患者的脑膜炎球菌疫苗接种情况
该回顾性数据库分析纳入2010年或2015年至2018年新诊断无脾患者,评估脑膜炎球菌ACWY和B疫苗接种率及影响因素。结果显示,诊断后3年内仅28.1%和9.7%的患者分别接种了MenACWY和MenB疫苗;接种肺炎球菌疫苗或至少一次健康访视与接种率较高相关。结论认为接种率低,需加强提供者教育和医疗可及性。
要点
- 新诊断无脾患者3年内MenACWY接种率28.1%,MenB仅9.7%。
- 接种肺炎球菌疫苗者更可能接种脑膜炎球菌疫苗(MenACWY HR 26.02)。
- 至少一次健康访视与接种率较高相关(MenB HR 11.17)。
核心结论
- 新诊断无脾患者的脑膜炎球菌疫苗接种率低,需教育提供者并确保脆弱患者获得医疗服务。
研究设计与样本
- 回顾性数据库分析,使用美国行政索赔数据库,纳入新诊断无脾患者(排除镰状细胞病),要求入组前连续12个月及入组后至少6个月,年龄≥2岁(MenACWY)或≥10岁(MenB)。
- MenACWY分析纳入2273例患者,MenB分析纳入741例患者。
主要发现
- 新诊断无脾后3年内,28.1%的患者接种了MenACWY疫苗,9.7%的患者接种了MenB疫苗。
- 接种肺炎球菌疫苗与接种脑膜炎球菌疫苗相关:MenACWY HR 26.02(95%CI 21.01-32.22),MenB HR 3.89(95%CI 2.07-7.29)。
- 至少一次健康访视与接种脑膜炎球菌疫苗相关:MenACWY HR 6.63(95%CI 4.84-9.09),MenB HR 11.17(95%CI 3.02-41.26)。
关键数值与推荐
- 美国推荐无脾患者接种MenACWY和MenB疫苗。
临床怎么用
- 临床医生应识别无脾患者并遵循指南推荐接种脑膜炎球菌疫苗。
- 接种肺炎球菌疫苗和定期健康访视可能促进脑膜炎球菌疫苗接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with asplenia are recommended to receive meningococcal ACWY (MenACWY) and B (MenB) vaccines in the United States (US). OBJECTIVES: To examine uptake and time to receipt of meningococcal vaccines in newly diagnosed asplenia patients, and identify factors associated with vaccination. METHODS: For this retrospective database analysis, patients were identified from 1/1/2010 (MenACWY) or 1/1/2015 (MenB) through 3/31/2018 from an administrative claims database including commercially insured US patients with ≥1 inpatient or ≥2 outpatient claims with evidence of a new asplenia diagnosis (sickle cell disease was excluded); continuous enrollment for ≥12 months before and ≥6 months after the index date; and age ≥2 (MenACWY) or ≥10 (MenB) years. Co-primary outcomes were uptake and time to receipt of ≥1 dose, separately for MenACWY and MenB, by Kaplan-Meier analysis. Cox proportional hazards regression models were used to identify characteristics associated with vaccination. RESULTS: Among 2,273 and 741 patients eligible for the MenACWY and MenB analyses, respectively, 28.1% and 9.7% received MenACWY and MenB in the first 3 years after a new asplenia diagnosis. Patients were more likely to receive meningococcal vaccines if they had received pneumococcal vaccines (MenACWY: hazard ratio [HR] 26.02; 95% confidence interval [CI] 21.01-32.22; MenB: HR 3.89; 95% CI 2.07-7.29) or attended ≥1 well-care visit (MenACWY: HR 6.63; 95% CI 4.84-9.09; MenB: HR 11.17; 95% CI 3.02-41.26). CONCLUSIONS: Meningococcal vaccination rates among newly diagnosed asplenia patients were low, highlighting the need to educate providers about the recommendations for high-risk conditions and ensure healthcare access for vulnerable patients.
引用
- Ghaswalla PK, Bengtson LGS, Marshall GS, et al. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States. Vaccine. 2020. PMID: 33309081. doi:10.1016/j.vaccine.2020.11.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。